Research Methodologies Followed in This Study: Primary Research:
Extensive primary research was conducted after acquiring knowledge about the patient blood management market scenario through secondary research. A significant number of primary interviews were conducted with both the demand (healthcare providers, blood bank operators, physicians, and blood bank technicians) and supply sides (developers, manufacturers, and distributors of patient blood management products).
The primaries interviewed for this study include experts from the patient blood management industry (such as CEOs, VPs, directors, sales heads, and marketing managers of tier 1, 2, and 3 companies engaged in offering patient blood management products across the globe), purchase managers in healthcare provider organizations, blood banks, blood collection centers, plasma collection centers, and CROs.
Secondary Research: This research study involved the extensive use of secondary sources, directories, and databases (such as D&B Hoovers, Bloomberg Businessweek, and Factiva), along with government databases, which were used to identify and collect information for this method-based, market-oriented, and commercial study of the market.
Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131352979 Global Revenue Growth: The patient blood management market is projected to reach USD 15.3 billion by 2024 from USD 10.7 billion in 2019, at a CAGR of 7.4% from 2019 to 2024.
Emerging Growth Boosters: Globally, the demand for donated blood is increasing because of greater volume of sophisticated medical surgical procedures conducted and the increasing number of trauma cases due to road accidents. These procedures require blood transfusions to make up for blood loss incurred during the procedures. Thus, the rising number of accidents, trauma cases, and surgical procedures performed are contributing to the market growth, thereby increasing the need for patient blood management products.
Recent Developments: # In 2019, Abbott (US) received the US FDA approval for its ‘Alinity s’ blood culture screening system as well as the Afinion HbA1c Dx assay kit. # In 2019, F. Hoffmann-La Roche LTD (Switzerland) received the US FDA approval for its cobas Babesia Test for donor screening. # In 2018, Terumo BCT (Japan) and Stafa Cellular Therapy (US) entered into a collaborative agreement. Based on this agreement, Terumo BCT expands access to the StafaCT software to healthcare organizations. # In 2018, B. Braun Melsungen AG (Ireland) acquired the bloodlines business of NxStage Medical, Inc. (US), which operates under the Medisystems brand. # In 2018, Abbott (US) received a CE mark for its Alinity h-series to be used in the European Union.
The Asia Pacific region is expected to register significant growth during the forecast period of 2019-2024 The patient blood management market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The Asia Pacific blood management market is expected to register significant growth over the forecast period due to the modernization of healthcare infrastructure, increasing prevalence of chronic lifestyle diseases, and rising awareness about blood donation & blood safety. China accounted for a major share of the Asia Pacific market, owing to a large patient pool and favorable government guidelines to improve healthcare infrastructure in the country.
Key Questions Addressed by the Report: # What are the growth opportunities related to the adoption of patient blood management solutions across the globe in the future? # Which product segment will register the highest adoption rate during the forecast period? # Where will the advancements in products offered by various companies take the industry in the mid- to long-term? # Emerging countries have immense opportunities for the growth of the market. Will this scenario continue in the next five years? # Which end users are estimated to adopt patient blood management systems? # What are the key strategies adopted by the key players operating in the market?
Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=131352979 Major Leaders: The prominent players in the patient blood management market include Haemonetics Corporation (US), Fresenius SE & Co. KGaA (Germany), Terumo Corporation (Japan), Immucor, Inc. (US), B. Braun Melsungen AG (Ireland), Macopharma (US), bioMérieux SA (France), Asahi Kasei Corporation (Japan), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), Grifols, S.A. (Spain), F. Hoffmann-La Roche Ltd. (Switzerland), LivaNova PLC (UK), Danaher Corporation (US), Mediware Information Systems (US), Kawasumi Laboratories, Inc.(Japan), Haier Biomedical (China), Diatron (Hungary), and BAG Diagnostics GmbH (Germany), among others.
An analysis of market developments between 2016 and 2019 revealed that several growth strategies such as product launches and enhancements, collaborations, partnerships, agreements, and strategic acquisitions were adopted by market players to strengthen their product portfolios and maintain a competitive position in the patient blood management market.